List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5301510/publications.pdf Version: 2024-02-01

		218677	149698
122	3,635	26	56
papers	citations	h-index	g-index
100	100	100	1050
123	123	123	4959
all docs	docs citations	times ranked	citing authors

YOSHIFUMI SAISHO

#	Article	IF	CITATIONS
1	Impaired early phase insulin secretion associated with gestational diabetes mellitus in underweight women. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 2411-2413.	1.5	2
2	Predicting non-insulin-dependent state in patients with slowly progressive insulin-dependent (type 1) diabetes mellitus or latent autoimmune diabetes in adults. Diabetologia, 2022, 65, 250-251.	6.3	1
3	Changes in glycemic variability, gastric emptying and vascular endothelial function after switching from twice-daily to once-weekly exenatide in patients with type 2 diabetes: a subpopulation analysis of the twin-exenatide study. BMC Endocrine Disorders, 2022, 22, 20.	2.2	3
4	DNA methylation analysis of cord blood samples in neonates born to gestational diabetes mothers diagnosed before 24 gestational weeks. BMJ Open Diabetes Research and Care, 2022, 10, e002539.	2.8	6
5	DPP-4 inhibitors and beta cell mass in Japanese adults with type 2 diabetes. Endocrine Practice, 2022, , .	2.1	0
6	Exenatide Once Weekly for Management of Type 2 Diabetes: A Review. Clinical Pharmacology: Advances and Applications, 2022, Volume 14, 19-26.	1.2	2
7	Inverse Association Between Fatty Liver at Baseline Ultrasonography and Remission of Type 2 Diabetes Over a 2-Year Follow-up Period. Clinical Gastroenterology and Hepatology, 2021, 19, 556-564.e5.	4.4	11
8	Predictors of later insulin therapy for gestational diabetes diagnosed in early pregnancy. Endocrine Journal, 2021, 68, 1321-1328.	1.6	3
9	RELATIONSHIP BETWEEN SERUM TOTAL BILIRUBIN CONCENTRATION AND MACROVASCULAR COMPLICATIONS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS. Journal of Hypertension, 2021, 39, e208.	0.5	0
10	Reduced beta cell number rather than size is a major contributor to beta cell loss in type 2 diabetes. Diabetologia, 2021, 64, 1816-1821.	6.3	13
11	New strategy for diagnosing abnormal glucose tolerance before 24 gestational weeks during the coronavirus disease 2019 pandemic. Journal of Diabetes Investigation, 2021, 12, 2104-2105.	2.4	1
12	Association of visitâ€toâ€visit glycemic variability with risk of cardiovascular diseases in highâ€risk Japanese patients with type 2 diabetes: A subanalysis of the EMPATHY trial. Journal of Diabetes Investigation, 2021, 12, 2190-2196.	2.4	11
13	Epigenetic Changes in Neonates Born to Mothers With Gestational Diabetes Mellitus May Be Associated With Neonatal Hypoglycaemia. Frontiers in Endocrinology, 2021, 12, 690648.	3.5	5
14	Revisiting Regulators of Human β-cell Mass to Achieve β-cell–centric Approach Toward Type 2 Diabetes. Journal of the Endocrine Society, 2021, 5, bvab128.	0.2	7
15	Clinical utility of 1â€month postpartum random plasma glucose and glycated hemoglobin combined with preâ€pregnancy body mass index for detecting postpartum glucose intolerance in Japanese women with gestational diabetes. Journal of Diabetes Investigation, 2021, , .	2.4	1
16	Efficacy and safety of onceâ€weekly exenatide after switching from twiceâ€daily exenatide in patients with typeÂ2 diabetes. Journal of Diabetes Investigation, 2020, 11, 382-388.	2.4	5
17	Beta-Cell Mass in Obesity and Type 2 Diabetes, and Its Relation to Pancreas Fat: A Mini-Review. Nutrients, 2020, 12, 3846.	4.1	56
18	Relationship between daily and visit-to-visit glycemic variability in patients with type 2 diabetes. Endocrine Journal, 2020, 67, 877-881.	1.6	13

#	Article	IF	CITATIONS
19	SGLT2 Inhibitors: The Star in the Treatment of Type 2 Diabetes?. Diseases (Basel, Switzerland), 2020, 8, 14.	2.5	56
20	An emerging new concept for the management of type 2 diabetes with a paradigm shift from the glucose-centric to beta cell-centric concept of diabetes - an Asian perspective. Expert Opinion on Pharmacotherapy, 2020, 21, 1565-1577.	1.8	13
21	Usefulness of the index calculated as the product of levels of fasting plasma glucose and hemoglobin A1c for insulinoma screening. Endocrine Journal, 2020, 67, 509-513.	1.6	3
22	Association of glucose tolerance status with pancreatic β―and α ell mass in communityâ€based autopsy samples of Japanese individuals: The Hisayama Study. Journal of Diabetes Investigation, 2020, 11, 1197-1206.	2.4	11
23	Associations of birthweight and history of childhood obesity with beta cell mass in Japanese adults. Diabetologia, 2020, 63, 1199-1210.	6.3	12
24	Longitudinal association of fatty pancreas with the incidence of type-2 diabetes in lean individuals: a 6-year computed tomography-based cohort study. Journal of Gastroenterology, 2020, 55, 712-721.	5.1	26
25	A new diagnostic strategy for gestational diabetes during the <scp>COVID</scp> â€19 pandemic for the Japanese population. Diabetes/Metabolism Research and Reviews, 2020, 36, e3351.	4.0	16
26	Pancreatic alpha-cell mass across adult human lifespan. European Journal of Endocrinology, 2020, 182, 219-231.	3.7	9
27	Cardiorenal Protection: Potential of SGLT2 Inhibitors and GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. Diabetes Therapy, 2019, 10, 1733-1752.	2.5	47
28	Glycemic and metabolic features in gestational diabetes: singleton <i>versus</i> twin pregnancies. Endocrine Journal, 2019, 66, 647-651.	1.6	11
29	Efficacy and safety of switching to insulin glargine 300 U/mL from 100 U/mL in Japanese patients with type 2 diabetes: AÂ12-month retrospective analysis. Heliyon, 2019, 5, e01257.	3.2	0
30	Usefulness of hemoglobin A1c and glycated albumin measurements for insulinoma screening: an observational case-control study. BMC Cancer, 2019, 19, 174.	2.6	4
31	Changing the Concept of Type 2 Diabetes: Beta Cell Workload Hypothesis Revisited. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2019, 19, 121-127.	1.2	13
32	Clinical and genetic characteristics of abnormal glucose tolerance in Japanese women in the first year after gestational diabetes mellitus. Journal of Diabetes Investigation, 2019, 10, 817-826.	2.4	8
33	Comprehensive study on human pancreatic β-cell regulatory mechanism. Impact, 2019, 2019, 38-40.	0.1	0
34	Signaling between pancreatic β cells and macrophages via S100 calcium-binding protein A8 exacerbates β-cell apoptosis and islet inflammation. Journal of Biological Chemistry, 2018, 293, 5934-5946.	3.4	32
35	Difference of seasonal variation between glycated albumin and glycated haemoglobin. Annals of Clinical Biochemistry, 2018, 55, 583-587.	1.6	7
36	A13875 Relationships among long-term blood glucose and blood pressure fluctuation and complications. Journal of Hypertension, 2018, 36, e215.	0.5	0

#	Article	IF	CITATIONS
37	A12656 Hypertension and hypobilirubinemia are risk factors for microvascular complications in hypertensive patients complicated by type 2 diabetes. Journal of Hypertension, 2018, 36, e213.	0.5	0
38	Lower serum total bilirubin concentration is associated with higher prevalence of gestational diabetes mellitus in Japanese pregnant women. Endocrine Journal, 2018, 65, 1199-1208.	1.6	6
39	Use of Diabetes Treatment Satisfaction Questionnaire in Diabetes Care: Importance of Patient-Reported Outcomes. International Journal of Environmental Research and Public Health, 2018, 15, 947.	2.6	78
40	Management of Dyslipidemia in Type 2 Diabetes: Recent Advances in Nonstatin Treatment. Diseases (Basel, Switzerland), 2018, 6, 44.	2.5	3
41	Association of Maternal Factors with Perinatal Complications in Pregnancies Complicated with Diabetes: A Single-Center Retrospective Analysis. Journal of Clinical Medicine, 2018, 7, 5.	2.4	8
42	Association between severity of obstructive sleep apnea and glycated hemoglobin level in Japanese individuals with and without diabetes. Endocrine Journal, 2018, 65, 121-127.	1.6	15
43	Incretin-based therapy and pancreatitis: accumulating evidence and unresolved questions. Annals of Translational Medicine, 2018, 6, 131-131.	1.7	18
44	Efficiency and Safety of New Insulin Infusion Protocol for Japanese Patients After Open-Heart Surgery. , 2018, 1, .		0
45	Pancreas Fat and Î ² Cell Mass in Humans With and Without Diabetes: An Analysis in the Japanese Population. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3251-3260.	3.6	24
46	Association of common polymorphisms with gestational diabetes mellitus in Japanese women: A case-control study. Endocrine Journal, 2017, 64, 463-475.	1.6	21
47	Ethnic Similarities and Differences in the Relationship between Beta Cell Mass and Diabetes. Journal of Clinical Medicine, 2017, 6, 113.	2.4	26
48	Pancreas Volume and Fat Deposition in Diabetes and Normal Physiology: Consideration of the Interplay Between Endocrine and Exocrine Pancreas. Review of Diabetic Studies, 2016, 13, 132-147.	1.3	43
49	Postprandial C-Peptide to Glucose Ratio as a Marker of β Cell Function: Implication for the Management of Type 2 Diabetes. International Journal of Molecular Sciences, 2016, 17, 744.	4.1	63
50	Relationship between indices of daily glycemic variability and long-term glucose fluctuations. Diabetes Research and Clinical Practice, 2016, 120, S121.	2.8	0
51	Effects of Obesity and Diabetes on α- and β-Cell Mass in Surgically Resected Human Pancreas. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 2874-2882.	3.6	41
52	Time-dependent changes in insulin requirement for maternal glycemic control during antenatal corticosteroid therapy in women with gestational diabetes: a retrospective study. Endocrine Journal, 2016, 63, 101-104.	1.6	15
53	OS 33-07 LOW SERUM ALBUMIN CONCENTRATION IN HYPERTENSIVE PATIENTS COMPLICATED BY TYPE 2 DIABETES IS ASSOCIATED WITH MICROVASCULAR COMPLICATIONS. Journal of Hypertension, 2016, 34, e394-e395.	0.5	0
54	PS 11-42 HIGH SYSTOLIC BLOOD PRESSURE AND LOW SERUM BILIRUBIN CONCENTRATION IN TYPE 2 DIABETES ARE ASSOCIATED WITH DIABETIC RETINOPATHY. Journal of Hypertension, 2016, 34, e345.	0.5	0

#	Article	IF	CITATIONS
55	The pancreas in humans with and without diabetes. Diabetologia, 2016, 59, 868-869.	6.3	2
56	Prevention of beta cell "karoshiâ€: a new paradigm for prevention and management of type 2 diabetes. Medical Research Archives, 2016, 4, .	0.2	2
57	Effects of Obesity and Diabetes on Beta-Cell Mass in Japanese. Pancreas (Fairfax, Va), 2016, 1, e11-e13.	1.5	0
58	Efficacy and safety of liraglutide monotherapy compared with metformin in Japanese overweight/obese patients with type 2 diabetes. Endocrine Journal, 2015, 62, 399-409.	1.6	22
59	A Reduction of HbA1c after 3 Months Predicts 2-year Responsiveness to Sitagliptin Treatment. Internal Medicine, 2015, 54, 2981-2989.	0.7	4
60	Efficacy and Safety of Sitagliptin Added to Insulin in Japanese Patients with Type 2 Diabetes: The EDIT Randomized Trial. PLoS ONE, 2015, 10, e0121988.	2.5	26
61	Metformin and Inflammation: Its Potential Beyond Glucose-lowering Effect. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2015, 15, 196-205.	1.2	336
62	β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes. World Journal of Diabetes, 2015, 6, 109.	3.5	173
63	Serum C-peptide to plasma glucose ratio may be associated with efficacy of vildagliptin in Japanese patients with type 2 diabetes mellitus. Diabetology International, 2015, 6, 197-205.	1.4	3
64	Relationships among different glycemic variability indices obtained by continuous glucose monitoring. Primary Care Diabetes, 2015, 9, 290-296.	1.8	29
65	C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetes. Diabetes Research and Clinical Practice, 2015, 108, 441-447.	2.8	7
66	Effects of Glucocorticoid Treatment on β- and α-Cell Mass in Japanese Adults With and Without Diabetes. Diabetes, 2015, 64, 2915-2927.	0.6	17
67	Alogliptin benzoate for management of type 2 diabetes. Vascular Health and Risk Management, 2015, 11, 229.	2.3	14
68	Effects of Liraglutide Monotherapy on Beta Cell Function and Pancreatic Enzymes Compared with Metformin in Japanese Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Subpopulation Analysis of the KIND-LM Randomized Trial. Clinical Drug Investigation, 2015, 35, 675-684.	2.2	14
69	Investigation of serum antibody titers for periodontopathic bacteria in diabetic patients. Journal of Japanese Society of Periodontology, 2015, 56, 414-422.	0.1	Ο
70	Importance of Beta Cell Function for the Treatment of Type 2 Diabetes. Journal of Clinical Medicine, 2014, 3, 923-943.	2.4	46
71	Obesity, Type 2 Diabetes and Beta Cell Failure: An Asian Perspective. Journal of Molecular and Genetic Medicine: an International Journal of Biomedical Research, 2014, s1, .	0.1	10
72	Glycemic Variability and Oxidative Stress: A Link between Diabetes and Cardiovascular Disease?. International Journal of Molecular Sciences, 2014, 15, 18381-18406.	4.1	136

#	Article	IF	CITATIONS
73	Factors associated with glycemic variability in Japanese patients with diabetes. Diabetology International, 2014, 5, 36-42.	1.4	19
74	Islet Number Rather Than Islet Size Is a Major Determinant of β- and α-Cell Mass in Humans. Journal of Clinical Endocrinology and Metabolism, 2014, 99, 1733-1740.	3.6	17
75	Effect of single tablet of fixed-dose amlodipine and atorvastatin on blood pressure/lipid control, oxidative stress, and medication adherence in type 2 diabetic patients. Diabetology and Metabolic Syndrome, 2014, 6, 56.	2.7	7
76	Lower beta cell function relates to sustained higher glycated albumin to glycated hemoglobin ratio in Japanese patients with type 2 diabetes. Endocrine Journal, 2014, 61, 149-157.	1.6	19
77	Clinical impact of women with gestational diabetes mellitus by the new consensus criteria: two year experience in a single institution in Japan. Endocrine Journal, 2014, 61, 353-358.	1.6	31
78	Pancreas Volume With Obesity in Asians. Pancreas, 2014, 43, 657-659.	1.1	10
79	Relationship between body mass index and pancreas volume in Japanese people. JOP: Journal of the Pancreas, 2014, 15, 626-7.	1.5	15
80	Maternally Inherited Diabetes and Deafness (MIDD) with Undetectable CPeptide Level and Cerebellar Atrophy. Journal of Clinical Case Reports, 2014, 04, .	0.0	0
81	Effects of Mitiglinide, a Short-Acting Insulin Secretagogue, on Daily Glycemic Variability and Oxidative Stress Markers in Japanese Patients with Type 2 Diabetes Mellitus. Clinical Drug Investigation, 2013, 33, 563-570.	2.2	14
82	Dipeptidyl peptidase-4 inhibitors and angioedema: a class effect?. Diabetic Medicine, 2013, 30, e149-e150.	2.3	14
83	Inhibition of NO-induced β-cell death by novel NF-κB inhibitor (â~)-DHMEQ via activation of Nrf2–ARE pathway. Biochemical and Biophysical Research Communications, 2013, 433, 181-187.	2.1	5
84	Postprandial serum C-peptide to plasma glucose ratio predicts future insulin therapy in Japanese patients with type 2 diabetes. Acta Diabetologica, 2013, 50, 987-988.	2.5	16
85	Change in β-Cell Mass in Japanese Nondiabetic Obese Individuals. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 3724-3730.	3.6	57
86	Response to Comment on: Saisho et al. β-Cell Mass and Turnover in Humans: Effects of Obesity and Aging. Diabetes Care 2013;36:111–117. Diabetes Care, 2013, 36, e112-e112.	8.6	6
87	Past Obesity as well as Present Body Weight Status Is a Risk Factor for Diabetic Nephropathy. International Journal of Endocrinology, 2013, 2013, 1-5.	1.5	12
88	Relationship between Stage of Diabetic Retinopathy and Pulse Wave Velocity in Japanese Patients with Type 2 Diabetes. Journal of Diabetes Research, 2013, 2013, 1-4.	2.3	19
89	β-Cell Mass and Turnover in Humans. Diabetes Care, 2013, 36, 111-117.	8.6	330
90	Marked decline in beta cell function during pregnancy leads to the development of glucose intolerance in Japanese women. Endocrine Journal, 2013, 60, 533-539.	1.6	19

#	Article	IF	CITATIONS
91	Study on the mechanism causing elevation of serum CA19-9 levels in diabetic patients. Endocrine Journal, 2013, 60, 885-891.	1.6	34
92	Antenatal management of recurrent fetal goitrous hyperthyroidism associated with fetal cardiac failure in a pregnant woman with persistent high levels of thyroid-stimulating hormone receptor antibody after ablative therapy. Endocrine Journal, 2013, 60, 1281-1287.	1.6	13
93	Association between beta cell function and future glycemic control in patients with type 2 diabetes. Endocrine Journal, 2013, 60, 517-523.	1.6	28
94	C-Reactive Protein, High-Molecular-Weight Adiponectin and Development of Metabolic Syndrome in the Japanese General Population: A Longitudinal Cohort Study. PLoS ONE, 2013, 8, e73430.	2.5	14
95	Relationship between periodontal disease and diabetic complications. Journal of Japanese Society of Periodontology, 2013, 54, 336-345.	0.1	2
96	Association between beta cell function and future glycemic control in patients with type 2 diabetes. Endocrine Journal, 2013, 60, 517-23.	1.6	21
97	Marked decline in beta cell function during pregnancy leads to the development of glucose intolerance in Japanese women. Endocrine Journal, 2013, 60, 533-9.	1.6	14
98	Antepartum Oral Disposition Index as a Predictor of Glucose Intolerance Postpartum. Diabetes Care, 2012, 35, e32-e32.	8.6	5
99	Effect of obesity on declining beta cell function after diagnosis of type 2 diabetes: a possible link suggested by cross-sectional analysis. Endocrine Journal, 2012, 59, 187-195.	1.6	18
100	Effects of Olmesartan Medoxomil, an Angiotensin II Type 1 Receptor Antagonist, on Plasma Concentration of B-Type Natriuretic Peptide, in Hypertensive Patients with Type 2 Diabetes Mellitus. Clinical Drug Investigation, 2011, 31, 237-245.	2.2	4
101	Insulin glulisine may ameliorate nocturnal hypoglycemia related to insulin antibody – A case report. Diabetes Research and Clinical Practice, 2011, 94, e53-e54.	2.8	15
102	Prediction of recovery time from hypoglycemia in patients with insulin overdose. Endocrine Journal, 2011, 58, 607-611.	1.6	16
103	Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes. Endocrine Journal, 2011, 58, 315-322.	1.6	76
104	Glycated albumin to glycated hemoglobin ratio reflects postprandial glucose excursion and relates to beta cell function in both type 1 and type 2 diabetes. Diabetology International, 2011, 2, 146-153.	1.4	53
105	Ongoing β-Cell Turnover in Adult Nonhuman Primates Is Not Adaptively Increased in Streptozotocin-Induced Diabetes. Diabetes, 2011, 60, 848-856.	0.6	35
106	Beta cell dysfunction and its clinical significance in gestational diabetes. Endocrine Journal, 2010, 57, 973-980.	1.6	50
107	Reply to Dr. Retnakaran. Endocrine Journal, 2010, 57, 1009-1010.	1.6	1
108	Pancreatic β-cell function and fetal growth in gestational impaired glucose tolerance. Acta Obstetricia Et Gynecologica Scandinavica, 2010, 89, 769-775.	2.8	13

#	Article	IF	CITATIONS
109	Usefulness of C-Reactive Protein to High-Molecular-Weight Adiponectin Ratio to Predict Insulin Resistance and Metabolic Syndrome in Japanese Men. Journal of Atherosclerosis and Thrombosis, 2010, 17, 944-952.	2.0	5
110	¹¹ C-Dihydrotetrabenazine PET of the Pancreas in Subjects with Long-Standing Type 1 Diabetes and in Healthy Controls. Journal of Nuclear Medicine, 2009, 50, 382-389.	5.0	116
111	Development of factors to convert frequency to rate for β-cell replication and apoptosis quantified by time-lapse video microscopy and immunohistochemistry. American Journal of Physiology - Endocrinology and Metabolism, 2009, 296, E89-E96.	3.5	12
112	Dynamics of β-cell turnover: evidence for β-cell turnover and regeneration from sources of β-cells other than β-cell replication in the HIP rat. American Journal of Physiology - Endocrinology and Metabolism, 2009, 297, E323-E330.	3.5	23
113	Relationship between pancreatic vesicular monoamine transporter 2 (VMAT2) and insulin expression in human pancreas. Journal of Molecular Histology, 2008, 39, 543-551.	2.2	80
114	β-Cell Replication Is the Primary Mechanism Subserving the Postnatal Expansion of β-Cell Mass in Humans. Diabetes, 2008, 57, 1584-1594.	0.6	616
115	Pancreatic Fat Content and β-Cell Function in Men With and Without Type 2 Diabetes. Diabetes Care, 2008, 31, e38-e38.	8.6	12
116	Combination of C-reactive Protein and High Molecular Weight (HMW)-Adiponectin Reflects Further Metabolic Abnormalities Compared with Each of Them Alone in Japanese Type 2 Diabetic Subjects. Endocrine Journal, 2008, 55, 331-338.	1.6	8
117	Effects of DHMEQ, a Novel Nuclear FactorKAPPA.B Inhibitor, on Beta Cell Dysfunction in INS-1 Cells. Endocrine Journal, 2008, 55, 433-438.	1.6	4
118	Effects of 12-Month Valsartan Therapy on Glycation and Oxidative Stress Markers in Type 2 Diabetic Subjects With Hypertension. International Heart Journal, 2008, 49, 681-689.	1.0	23
119	Relationship between proinsulin-to-insulin ratio and advanced glycation endproducts in Japanese type 2 diabetic subjects. Diabetes Research and Clinical Practice, 2007, 78, 182-188.	2.8	18
120	Effect of valsartan, an angiotensin II receptor blocker, on markers of oxidation and glycation in Japanese type 2 diabetic subjects: Blood pressure-independent effect of valsartan. Diabetes Research and Clinical Practice, 2006, 74, 201-203.	2.8	43
121	Two Cases in which an Abnormal Hemoglobin (Hb Kamakura) was Identified on the Basis of an Abnormally Low Glycohemoglobin Levels. Internal Medicine, 2003, 42, 595-598.	0.7	1
122	Pneumonitis Induced by Ou-gon (Scullcap) Internal Medicine, 2001, 40, 764-768.	0.7	39